Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
05 Settembre 2023 - 2:00PM
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical
company focused on developing and commercializing novel treatments
for gastrointestinal diseases, announced today that members of its
management team will participate in the following upcoming investor
conferences:
- Morgan Stanley 21st Annual
Global Healthcare Conference in New York City. Management
will participate in one-on-one meetings on September 12, 2023.
- H.C. Wainwright 25th
Annual Global Investment Conference in New York
City. Management will participate in a fireside chat on Wednesday,
September 13, 2023 at 2:30 p.m. EDT and one-on-one meetings
throughout the day.
To access the live webcast and archived recording of the
fireside chat, visit the News & Events section of the Phathom
website at
https://investors.phathompharma.com/news-events/events-and-presentations.
The recording will be available for 90 days following the
event.
About Phathom Pharmaceuticals, Inc.Phathom
Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of novel treatments for
gastrointestinal diseases. Phathom has in-licensed the exclusive
rights in the United States, Europe, and Canada to vonoprazan, a
first-in-class potassium-competitive acid blocker (PCAB). For more
information about Phathom, visit the Company’s website
at www.phathompharma.com and follow the
Company on LinkedIn and Twitter.
MEDIA CONTACTNick
Benedetto1-877-742-8466media@phathompharma.com
INVESTOR CONTACTEric
Sciorilli1-877-742-8466ir@phathompharma.com
© 2023 Phathom Pharmaceuticals. All rights reserved.
Grafico Azioni Phathom Pharmaceuticals (NASDAQ:PHAT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Phathom Pharmaceuticals (NASDAQ:PHAT)
Storico
Da Giu 2023 a Giu 2024